  The clinical success achieved using CD19-directed CAR-T cells has stimulated many academic institutions to explore the feasibility of manufacturing these , and other CAR-T cells , in-house. This article reviews the issues that must be addressed in order to achieve this goal. It includes the manufacturing infrastructure , the regulatory environment , practical aspects of production , and the costs involved.